Opaleye Management »

Biodesix shares owned by Opaleye Management

Quarter-by-quarter ownership of Biodesix (BDSX) shares owned by Opaleye Management from 13F filings

Historical chart of Opaleye Management investment in Biodesix

Tip: Access up to 7 years of quarterly data

All positions including Biodesix held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biodesix by Opaleye Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $914k 497k 1.84
2023-09-30 $752k 456k 1.65

More positions owned by Opaleye Management

Harrow Health (HROW)
Tg Therapeutics (TGTX)
Acelyrin (SLRN)
Rhythm Pharmaceuticals (RYTM)
Ocular Therapeutix (OCUL)
Catalyst Pharmaceutical Partners (CPRX)
Keros Therapeutics (KROS)
Ideaya Biosciences (IDYA)
Eton Pharmaceuticals (ETON)
Crinetics Pharmaceuticals In (CRNX)
Arvinas Ord (ARVN)
Codexis (CDXS)
Biohaven (BHVN)
Edgewise Therapeutics (EWTX)
Iovance Biotherapeutics (IOVA)

View all positions for Opaleye Management

Top funds holding Biodesix

AIGH Capital Management
Worth Venture Partners
Essex Investment Management
Wells Fargo & Company
Vanguard Group
Opaleye Management
Legato Capital Management
Peter B. Cannell & Co
HighTower Advisors
Hanson McClain Advisors
Millennium Management
William Blair $ Company
Telemark Asset Management
Oracle Investment Management
Jane Street

View all funds holding Biodesix